Most Recent Articles by Jonathan Goodman
Median overall survival increased from 10.1 months with anetumab ravtansine to 11.6 months with vinorelbine.
Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.
ROS1 and ALK rearrangements in patients with non-small cell lung cancer may predict different metastasis distributions at diagnosis.
Valuable information regarding patients' life expectancy can be collected through neutrophil-lymphocyte ratio biomarkers.
The randomzied, phase 3 CONVERT trial examined 547 patients with small-cell lung cancer.